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Abstract 
Depression and psychostimulant abuse are common comorbidities among humans with 
immunodeficiency virus (HIV) disease. The HIV regulatory protein TAT is one of multiple 
HIV-related proteins associated with HIV-induced neurotoxicity. TAT-induced dysfunction 
of dopamine and serotonin systems in corticolimbic brain areas may result in impaired 
reward function, thus, contributing to depressive symptoms and psychostimulant abuse. 
Transgenic mice with doxycycline-induced TAT protein expression in the brain (TAT+, 
TAT- control) show neuropathology resembling brain abnormalities in HIV+ humans. We 
evaluated brain reward function in response to TAT expression, nicotine and 
methamphetamine administration in TAT+ and TAT- mice using the intracranial self-
stimulation procedure. We evaluated the brain dopamine and serotonin systems with high-
performance liquid chromatography. The effects of TAT expression on delay-dependent 
working memory in TAT+ and TAT- mice using the operant delayed nonmatch-to-position 
task were also assessed. During doxycycline administration, reward thresholds were elevated 
by 20% in TAT+ mice compared with TAT- mice. After the termination of doxycycline 
treatment, thresholds of TAT+ mice remained significantly higher than those of TAT- mice 
and this was associated with changes in mesolimbic serotonin and dopamine levels. TAT+ 
mice showed a greater methamphetamine-induced threshold lowering compared with TAT- 
mice. TAT expression did not alter delay-dependent working memory. These results indicate 
that TAT expression in mice leads to reward deficits, a core symptom of depression, and a 
greater sensitivity to methamphetamine-induced reward enhancement. Our findings suggest 
that the TAT protein may contribute to increased depressive-like symptoms and continued 
methamphetamine use in HIV-positive individuals. 
Keywords: anhedonia, methamphetamine, cognition, dopamine, serotonin 
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1. Introduction 
Compromised reward and cognitive function after human immunodeficiency virus (HIV) 
infection may contribute to comorbid drug dependence and depressive symptoms. Impairments 
in the response to pleasure (i.e., reward deficits or anhedonia) represent a key feature of 
depression (Pizzagalli et al., 2005, Der-Avakian et al., 2014), and may explain increased rates 
of major depression/mood disorders after HIV infection and methamphetamine dependence 
(Kesby et al., 2015, Panee et al., 2015). In HIV-infected subjects, depressed moods, 
methamphetamine and nicotine dependence have all been associated with decreased 
likelihood to initiate highly active antiretroviral therapy (HAART) (Tegger et al., 2008, King 
et al., 2012). Moreover, depressive symptoms predict greater functional decline and cognitive 
complaints in patients (Sadek et al., 2007). Understanding the relationship between 
depressive and cognitive symptoms, drug dependence and HIV infection is critical to 
implementing effective therapeutic strategies.  
Both HIV infection and drugs of abuse, including methamphetamine, target subcortical 
brain structures (Volkow et al., 2001, Gorry et al., 2003, Wang et al., 2012) and 
dopaminergic systems in particular, which are critically involved in reward processes (Koob 
and Volkow, 2010). Therefore, impairments in dopaminergic transmission may be one of the 
mechanisms underlying reward deficits in people with HIV (Kaul and Lipton, 2006, Ferris et 
al., 2008). Moreover, damage to corticolimbic brain regions such as the basal ganglia, 
hippocampus, and cerebral cortex (Gorry et al., 2003) are also implicated in HIV-associated 
cognitive deficits (Heaton et al., 1995, Heaton et al., 2011). The substantial overlap between 
the associated damage to these brain regions and neurotransmitter systems after HIV 
infection suggests that reward function may be central to depressive symptoms, drug 
dependence and cognitive function. 
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In HIV-infected subjects on antiretroviral treatment, cognitive and depressive symptoms 
are still prevalent (Heaton et al., 2011), suggesting factors other than viral load may be 
involved. For example, we have previously shown that expression of HIV-associated gp120 
protein increases the sensitivity to methamphetamine and exacerbates cognitive impairments 
in mice (Kesby et al., 2014, Kesby et al., 2015). The viral TAT protein has also been 
implicated in HIV-induced neuropathology given its central role in the pathogenesis of HIV 
infection (for review, (Li et al., 2009)). Inducible transgenic mice that express the viral TAT 
protein in the brain, under the glial fibrillary acidic protein (GFAP) promoter, provide a 
useful in vivo model to study the temporal impact of TAT protein in brain function. TAT-
expressing mice show neuropathology similar to that observed in HIV-infected humans 
including apoptosis, astrocytosis, neurodegeneration of the cortex, degeneration of dendrites 
and inflammation (Kim et al., 2003). Recent imaging studies have revealed reduced gray 
matter density and cerebral fractional anisotropy abnormalities in multiple brain areas in 
TAT-expressing mice (Carey et al., 2013, Carey et al., 2015). TAT protein induces 
dysfunction of dopaminergic neurotransmission in corticolimbic brain circuits (Ferris et al., 
2009b, Zhu et al., 2009, Midde et al., 2012, Theodore et al., 2012) that are involved in reward 
function (Koob and Volkow, 2010). However, it is not known if TAT-induced alterations in 
dopaminergic function in corticolimbic circuits result in changes in reward processes. 
The goal of the present study was to determine the acute and persistent impact of TAT 
expression on brain reward function (specifically, reward deficits or anhedonia) and 
neurochemistry. Furthermore, whether TAT-induced impairments in reward function can 
predict impairments in working memory, a commonly observed deficit in HIV-infected 
patients (Heaton et al., 2004), was also determined. The use of a doxycycline-inducible 
transgenic mouse allowed for the assessment of both acute and prolonged effects of TAT 
expression in the adult mice. Brain reward function in response to TAT expression and acute 
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psychostimulant administration (nicotine and methamphetamine), was assessed in the 
intracranial self-stimulation (ICSS) procedure (Barnes et al., 2014). The ICSS procedure is 
particularly sensitive to alterations in limbic dopaminergic projections critical to the 
motivational aspects of anhedonia (Der-Avakian and Markou, 2012). In addition, 
dopaminergic and serotonergic function was assessed in the striatum at two time points after 
the doxycycline regimen by high-performance liquid chromatography (HPLC). Considering 
that subjects with HIV exhibit deficits in working memory (Heaton et al., 2011), delay-
dependent working memory was assessed in TAT-expressing mice using a spatial delayed 
nonmatch-to-position task (Woolley and Ballard, 2005). 
2. Materials and methods 
2.1. Animals 
For the ICSS study, a total of 30 male mice, with 16 mice containing either the GFAP-null 
alleles or the TAT protein transgene (TAT-) and 14 mice containing both the GFAP-null 
alleles and TAT protein transgene (TAT+) were used. An additional cohort of mice (n=6 
TAT- and n=6 TAT+ mice) were used to assess neurotransmitter function 3-days after 
completion of the doxycycline regimen. This time point ensured that TAT protein expression 
was still evident (Paris et al., 2014c) and differences in neurotransmitter content were not 
influenced by the acute effects of doxycycline treatment (i.e., the half-life of doxycycline in 
mice is approximately 170 min (Bocker et al., 1981)). For the DNMTP study, a total of 29 
male mice (n=15 TAT- and n=14 TAT+ mice) were used. Inducible TAT transgenic mouse 
colonies on a C57BL/6J background were obtained by generation of two separate transgenic 
lines Teton-GFAP mice and TRE-Tat86 mice, and then cross-breeding of these two lines of 
transgenic mice as previously described (Kim et al., 2003). The mice were housed in a 
humidity- and temperature-controlled animal facility on a 12 h/12 h reverse light/dark cycle 
(lights off at 7:00 AM). Mice used for the DNMTP study were housed in groups of 2-4 and 
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food deprived to 85% free-feeding weight, but had ad libitum access to water. Mice used for 
the ICSS study were housed individually after surgery with ad libitum access to food and 
water. Behavioral testing was conducted during the dark phase of the light/dark cycle. All of 
the experiments were conducted in accordance with the guidelines of the American 
Association for the Accreditation of Laboratory Animal Care and National Research 
Council’s Guide for the Care and Use of Laboratory Animals and approved by the University 
of California San Diego Institutional Animal Care and Use Committee. 
2.2. Intracranial self-stimulation 
The ICSS procedure was conducted as previously described (Stoker et al., 2008, Der-Avakian 
et al., 2014), detailed methods can be found in the Supplementary Materials. At 4 months of 
age, mice were anesthetized and a stainless steel bipolar electrode (0.20 mm diameter; 6 mm 
length; Plastics One, Roanoke, VA, USA) was implanted into the medial forebrain bundle 
using the following coordinates: anterior/posterior, +1.6 mm; medial/lateral, -1.0 mm; 
dorsal/ventral, -5.3 mm; from flat skull (Paxinos and Franklin, 2001). The mice were allowed 
seven post-surgery recovery days prior to commencing training. 
ICSS training and testing were conducted in eight Plexiglas operant chambers 
(30.5×24×27 cm; Med Associates, St. Albans, VT, USA). Mice were tested in the current-
threshold procedure. A test session consisted of four alternating series of descending and 
ascending current intensities, starting with a descending series. Blocks of three trials were 
presented to the subject at a given stimulation intensity, and the intensity changed by 4-5 µA 
steps between blocks of trials. The initial stimulus intensity was set approximately 30–40 µA 
above the baseline current-threshold for each animal. Each test session provided several 
dependent variables: threshold, response latency and timeout responses. The threshold value 
of each series was defined as the midpoint in microamperes between the current intensity 
level at which the animal made two or more positive responses out of the three stimulus 
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presentations and the level at which the animal made less than two positive responses. The 
animal's estimated reward threshold for each test session was the mean of the four series’ 
thresholds. The response latency was defined as the average time in seconds that elapsed 
between the delivery of the electrical stimulus and the turning of the wheel manipulandum for 
all of the trials that led to a positive response. Timeout responses were defined as the total 
number of responses that occurred during the intertrial interval for a test session. All mice 
were successfully trained in the ICSS task confirming correct electrode placement (Stoker 
and Markou, 2011).  
2.3. ICSS Experimental Timeline 
Mice underwent stereotaxic surgery and were subsequently trained to perform in the ICSS 
procedure until stable baseline reward threshold levels were achieved after at least 15 days of 
testing. Subsequently, all mice were treated with a doxycycline hyclate (DOX; Sigma, St. 
Louis, MO, USA) regimen consisting of 100 mg/kg, intraperitoneally (i.p.), once a day for 7 
days. This regimen was based on the previously demonstrated efficacy of TAT induction at 
this dose of DOX (Carey et al., 2012). Only mice containing both the GFAP-null alleles and 
TAT protein transgene (TAT+) generate TAT protein after DOX administration. To assess 
the acute effects of DOX, mice were tested 2-3 h after the first DOX administration. 
Subsequently, mice were tested daily in the ICSS procedure in the morning (08:00-11:00h) 
and given the remaining six DOX injections in the evening (17:00h). After the final DOX 
administration, mice were tested daily for 14 days. Then, using a within subject Latin square 
design, dose-response function for acute nicotine (12 days) followed by acute 
methamphetamine (19 days) were assessed. Acute subcutaneous nicotine (nicotine hydrogen 
tartrate; Sigma) injections at doses of 0.075, 0.15 and 0.3 mg/kg base were given 5 min 
before testing, three days apart. Acute methamphetamine (methamphetamine hydrochloride; 
Sigma) injections (i.p.) at doses of 0.25, 0.5 and 1 mg/kg were given 20 min before testing, 
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four days apart. The highest dose of methamphetamine (2 mg/kg) was given last, after 
administration of the all the other doses. Mice were euthanized three days after the final acute 
methamphetamine administration and the caudate putamen (CPu) and nucleus accumbens 
(Acb) dissected from the contralateral hemisphere to the electrode placement. Certain data 
from mice were excluded from the final analyses (see Supplementary Materials). 
2.4 High-performance liquid chromatography of neurotransmitters 
Brain neurochemistry was analyzed using a HPLC system with electrochemical detection as 
previously described (Kesby et al., 2009, Kesby et al., 2016), see Supplementary Materials 
for details. Catecholamine and indoleamine levels in the CPu and Acb were assessed for 
acute effects at three days and persistent effects at 40 days after the completion of the 
doxycycline regimen. Data was processed with Dionex Chromeleon software (v7.2, Thermo 
Scientific, CA, USA). 
2.5. Delayed nonmatch-to-position (DNMTP) testing 
The DNMTP task was established in the laboratory based on published literature (Woolley 
and Ballard, 2005), see Supplementary Materials for details. Briefly, DNMTP training and 
testing were conducted in twelve Plexiglas operant chambers (model ENV-307A, Med 
Associates Inc., St. Albans, VT, USA), each enclosed in a sound-attenuating cubicle. The 
nonmatch-to-position rule consisted of sample and choice stages during 60 trials in each daily 
session. During the sample stage, a single lever was presented and the stimulus light above 
the active lever was illuminated. The mouse was required to press the sample lever, which 
immediately retracted, and to nose poke into the food magazine to begin the choice stage. 
During the choice stage, both levers were presented and associated stimulus lights 
illuminated. Pressing the opposite lever to that previously presented at the sample stage 
resulted in the delivery of a single food reward (20 mg Sucrose pellet, TestDiet, IN, USA). If 
the mouse pressed the other lever it was recorded as an incorrect response and was 
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unrewarded. An incorrect response or failure to respond to either the sample or choice levers 
during the 10 s limited hold (i.e., an omission) resulted in a time out period (house lights on) 
of 5 s. The delay periods for DNMTP testing were 1, 2, 5, 10, 20 s. Delay intervals were 
presented in a pseudorandom manner forcing mice to continuously nosepoke during the delay 
period in order to avoid mediating behaviour. Correct responses were calculated as a 
percentage of the total trials (not including omissions) across all seven days. All other 
measures including the latencies to respond and collect reward were averaged to provide a 
single value of each performance variable for each mouse. 
After the acquisition of stable baseline performance (>80% correct responses on the two 
lowest delays over 3 days), mice were administered 7 daily DOX injections (see section 2.3) 
in the evening (17:00h) and tested daily in the morning (08:00-10:00 h) during DOX 
administration and for 7 days after the final DOX injection. At this stage, the delays were 
increased to 2, 5, 12, 24, 30 s (DNMTP2) for 4 days. Behavioral measures included 
percentage correct responses for the five delay time periods during each phase of testing 
(baseline, during DOX administration, post-DOX administration and the final DNMTP2 
testing). Number of omissions was calculated as the total number of missed trials during the 
session, i.e. no response to the lever or food magazine during the delay period. Latency 
measures included the amount of time (ms) the animals took to respond to the sample lever, 
choice levers (separated for correct and incorrect responses) and to collect the food reward.  
2.6. Statistical analyses 
All analyses were performed with IBM SPSS Statistics 20 (Armonk, NY, USA). Data were 
analyzed using analysis of variance (ANOVA), with TAT as the between-subject factor. 
Repeated-measures ANOVAs were used when within-subject factors were present. When 
appropriate, post hoc comparisons were performed using Least Significant Difference (LSD) 
analyses. ICSS threshold data were expressed as the percentage of baseline thresholds during 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
DOX administration and the post-DOX period, and as a percentage of saline treatment in 
experiments with acute nicotine and methamphetamine challenges. To determine if there 
were any effects of the nicotine and methamphetamine dosing order on reward thresholds, 
additional analyses were conducted with Dosing Group (4 groups used for the Latin square 
design) included as a between-subjects factor. ICSS timeout responses were expressed as the 
difference from baseline or saline responses as appropriate. Given the high variance in total 
amount, all neurochemicals were converted to a percentage of the TAT- mean and analysed 
accordingly. Data on DNMTP trials completed were analyzed using an ANOVA with Block 
(baseline week, DOX week (days immediately after DOX injections) and post-DOX week) as 
the repeated measure. The percentage of correct responses was calculated from all trials 
included in each seven- or four-day period (7-day: baseline, DOX and post-DOX; 4-day: 
DNMTP2), and analyzed with Block as the repeated measure. Mean latencies were analyzed 
using an ANOVA with Block (baseline, DOX, post-DOX and DNMTP2) as the repeated 
measure. Results are expressed as mean ± SEM. Differences were considered statistically 
significant at p<0.05. 
3. Results 
3.1. ICSS testing during doxycycline-induced TAT expression 
ICSS data were analyzed as four blocks of 7 days, consisting of the baseline, DOX (days 
immediately after DOX injections) and two post-DOX weeks (Figure 1). For reward 
thresholds (Figure 1A), there was a significant main effect of Block (F3,81=8.0, p<0.001) with 
reward thresholds significantly higher during DOX compared with thresholds during the 
baseline or post-DOX periods (p<0.01). There was also significant main effect of TAT 
(F1,27=9.1, p<0.01) and a significant interaction of Block x TAT (F3,81=4.6, p<0.01). TAT+ 
mice showed significantly higher reward thresholds than TAT- mice during DOX 
administration (p<0.001) and during the first (p<0.05) and second (p<0.05) post-DOX weeks.  
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For latencies (Figure 1B), there was a significant main effect of Block (F3,81=10.0, p<0.001) 
with the latency to respond significantly higher during DOX compared with the baseline or 
post-DOX periods (p<0.001). For timeout responses (Figure 1C), there was a significant 
main effect of Block (F3,81=8.5, p<0.001) with the number of timeout responses lower during 
DOX and post-DOX periods than at baseline (p<0.05). Timeout responses were also 
significantly lower during DOX compared with the first (p<0.05) and second (p<0.05) post-
DOX weeks. There were no differences between TAT- and TAT+ for reward thresholds 
(TAT-: 155.6±10.5%; TAT+: 144.6±14.2%), response latencies (TAT-: 4.07±0.11 s; TAT+: 
3.72±0.17 s) or timeout responses (TAT-: -184.3±85.4 responses; TAT+: -279.7±100.3 
responses) after acute DOX administration (2 h prior to testing, day 1). 
3.2. Effects of acute nicotine on brain reward function 
Acute nicotine administration did not alter reward thresholds (Figure 2A) in either TAT- or 
TAT+ mice with no significant effect of Dose or TAT detected. However, there was a 
significant main effect of Dose on the latency to respond (F3,75=6.2, p<0.01). The highest 
nicotine dose, 0.3 mg/kg, significantly increased response latency compared to saline 
(p<0.01) and 0.075 mg/kg (p<0.01)(Figure 2C). There was also a significant main effect of 
Dose on the number of timeout responses (F3,75=5.4, p<0.01) with all doses of nicotine 
decreasing timeout responses compared with saline treatment (p<0.05)(Figure 2E). Analysis 
of the dosing order on reward thresholds revealed no significant effects of Dosing Group or 
interaction of Dosing Group x TAT. 
3.3. The effects of acute methamphetamine on brain reward function 
Acute methamphetamine administration lowered reward thresholds (Figure 2B) with a 
significant main effect of Dose present (F4,88=10.0, p<0.001). A significant main effect of 
TAT (F1,22=6.5, p<0.05) was detected with TAT+ mice showing a greater reward threshold 
lowering after methamphetamine than TAT- mice. Compared with saline treated mice, TAT- 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
mice showed significantly threshold lowering after 0.5 and 1 mg/kg of methamphetamine 
(p<0.05); whereas TAT+ mice showed significantly threshold lowering after 0.5, 1 and 2 
mg/kg of methamphetamine (p<0.05). A significant interaction of Dose x TAT (F4,88=3.2, 
p<0.05) was detected for the response latency after methamphetamine (Figure 2D) with a 
greater response latency after 0.5 mg/kg methamphetamine observed in TAT+ mice 
compared to TAT- mice (p<0.05). For timeout responses (Figure 2F), there was a significant 
main effect of Dose (F4,88=9.9, p<0.001) with all doses of methamphetamine decreasing the 
number of timeout responses compared with saline (p<0.05). Furthermore, a stepwise effect 
was also observed with the higher doses of methamphetamine (1 and 2 mg/kg) reducing 
timeout responses more than the lower doses (0.25 and 0.5 mg/kg; p<0.05). Analysis of the 
dosing order on reward thresholds revealed no significant effects of Dosing Group or 
interaction of Dosing Group x TAT. Similarly, there were no significant effects of the 
nicotine Dosing Group for the response to methamphetamine.  
3.4. Dopamine and serotonin levels 
3.4.1. Effects of acute TAT expression on neurochemistry (3 days after doxycycline regimen) 
In the CPu (Figure 3A), TAT+ mice had increased levels of dopamine (F1,10=6.9, p<0.05) 
and 3-MT (F1,10=8.1, p<0.05) compared to TAT- mice. In the Acb (Figure 3B), TAT+ mice 
had increased levels of serotonin (F1,10=18.6, p<0.01) and 5-HIAA (F1,10=7.1, p<0.05) 
compared to TAT- mice. There was also a trend for decreased Acb levels of dopamine 
(F1,10=3.6, p<0.1) in TAT+ mice compared to TAT- mice 
3.4.2. Persistent effects of TAT expression on neurochemistry (40 days after doxycycline 
regimen) 
Prior TAT expression had no significant effect of dopaminergic or serotonergic function in 
either the CPu (Figure 3C) or Acb (Figure 3D).  
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3.5. DNMTP training and trials completed 
There were no significant differences between TAT- and TAT+ mice on the number of days 
to reach criterion in each training stage (Figure S1). Data on DNMTP trials completed were 
analyzed as three blocks of 7 days, consisting of the baseline, DOX (days immediately after 
DOX injections) and the post-DOX week (Figure 4). There were significant main effects of 
Block (F2,54=39.8, p<0.001) and Day (F6,162=7.7, p<0.001), and a significant interaction of 
Block x Day (F12,324=7.6, p<0.001) on the trials completed. All the blocks were significantly 
different from each other (p<0.01) with the greatest number of trials completed during the 
baseline period and the lowest number of trials completed during DOX administration. The 
effect of DOX was most severe initially, with mice gradually increasing the trials completed 
across the days of testing. There were no significant differences between TAT- and TAT+ 
mice on trials completed during DNMTP2 testing with increased delays. 
3.6. DNMTP testing 
The percentage of correct responses was calculated from all trials over seven days for the 
baseline, DOX and post-DOX periods, or four days for the DNMTP2 period. There were no 
differences between TAT- and TAT+ mice at any stage of testing (Figure 5). There was a 
significant main effect of Delay during baseline (F4,108=154.6, p<0.001), DOX (F4,108=141.3, 
p<0.001), post-DOX (F4,108=109.2, p<0.001) and DNMTP2 (F4,108=197.6, p<0.001). 
Performance decreased with delays greater than 2 s with each increase in delay further 
impairing performance during baseline, DOX and post-DOX (p<0.01). Mice tended to 
respond at chance levels (50% correct responses) at delays of 24 s or greater as demonstrated 
by a plateau in performance at 24 and 30 s delays in the DNMTP2 testing. 
Mean latencies were analyzed as four blocks (baseline, DOX, post-DOX and DNMTP2). 
There was a significant effect of Block for all response latencies (Figure 6) including the 
lever response during the sample stage (F3,81=57.9, p<0.001), correct responses during the 
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choice stage (F3,81=81.3, p<0.001), incorrect responses during the choice stage (F3,81=11.7, 
p<0.001) and reward collection (F3,81=40.7, p<0.001). In all cases, latencies were 
significantly greater during DOX administration compared with all other periods of testing 
(p<0.01). For both sample lever responses and incorrect responses, latencies were also 
significantly different during DNMTP2 testing than during baseline (p<0.05). There were no 
differences between TAT+ and TAT- mice in response latencies. 
4. Discussion 
The present study demonstrated that acute TAT protein expression led to reward deficits 
or anhedonia as demonstrated by elevated reward thresholds in the ICSS task. Furthermore, 
increased serotonergic function and decreased dopaminergic function were observed in the 
Acb of TAT+ mice at a time point associated with TAT-induced anhedonia. In addition, prior 
TAT exposure led to an increased sensitivity to methamphetamine-induced reward 
enhancement but did not affect nicotine-induced alterations in brain reward function. TAT 
expression did not affect delay-dependent working memory in the DNMTP task suggesting 
that alterations in brain reward function do not predict cognitive impairments, at least for this 
cognitive construct.  
Anhedonia reflects decreased interest or pleasure in rewarding stimuli and is a trait feature 
of major depressive disorder (Pizzagalli et al., 2005, Der-Avakian et al., 2014). Little is known 
about the effects of HIV-related proteins including TAT on depression-like behaviour in 
animal models, which remains an unmet need in HIV-related basic science research (Barreto 
et al., 2014). In the present study, we demonstrated that TAT protein expression led to a 
significant elevation in reward thresholds reflecting anhedonia. Consistent with our findings, 
intracerebroventricular administration of TAT protein in rats resulted in depression-like 
behavior in the forced swim test and sucrose-preference test (Lawson et al., 2011). Female 
HIV-1 transgenic rats have also been shown to exhibit a range of depression-like behaviors 
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(learned helplessness) and social anxiety (Nemeth et al., 2014). In addition, TAT expression 
alters other affective behaviors, such as anxiety-like behavior assessed in a variety of 
behavioral procedures (Paris et al., 2014b, Paris et al., 2014c, Hahn et al., 2015). Our findings 
demonstrate that expression of the TAT protein alone is sufficient to induce anhedonia and 
may contribute to comorbid depression in HIV-infected subjects. 
The motivational aspects of reward, which the ICSS procedure is most sensitive to, are 
thought to be driven primarily by dopaminergic projections from the ventral tegmental area to 
the Acb (Der-Avakian and Markou, 2012). For example, electrical self-stimulation increases 
dopamine release in the Acb (Owesson-White et al., 2008, Beyene et al., 2010). 
Psychostimulant administration potentiates stimulated dopamine release (Hernandez et al., 
2012) resulting in reward enhancement, that is lowering of reward thresholds. In contrast, 
anhedonia is reflected by ICSS threshold elevations and is associated with decreased 
dopamine transmission in the Acb (Carlezon et al., 2006). Consistent with this premise, 
assessment of neurotransmission 3 days after the final doxycycline treatment, when TAT 
protein expression (Paris et al., 2014c) and anhedonia (see Figure 1) is evident, revealed a 
trend for decreased dopamine levels in the Acb of TAT+ mice. In agreement with our data, 
TAT infusions into the Acb impair dopamine transporter function (Ferris et al., 2009a) and 
decrease stimulated dopamine release (Ferris et al., 2009b). Consistent with the effects of 
TAT in animal models and the high rate of comorbid depression, HIV-infected subjects have 
significantly reduced dopamine transporter density in the striatum (Chang et al., 2008) and 
decreased dopamine levels in cerebrospinal fluid (Berger et al., 1994). Thus, the suppressing 
effects of TAT protein on dopamine function in mesolimbic pathways may mediate the 
observed anhedonia in the present study and in HIV-infected subjects. The concomitant 
increase in dopamine and dopamine release (3-MT represents a proxy marker for dopamine 
release) in the CPu 3-days after doxycycline administration is somewhat perplexing. In vitro 
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studies have demonstrated decreased dopamine transporter function and uptake after TAT 
protein exposure (Zhu et al., 2009, Midde et al., 2012) which may partially explain increased 
levels of 3-MT. Increased dopamine levels may represent a compensatory response in 
striatonigral projections. Importantly, changes in Acb or CPu dopaminergic function were no 
longer present 11 (Kesby et al., 2016) or 40 days (see Figure 3C) after doxycycline treatment 
indicating no persistent effects of TAT expression on baseline levels of dopamine. 
The observed increases in serotonergic function in the Acb of TAT+ mice may also 
contribute to TAT-induced anhedonia. Consistent with our findings, systemic treatments that 
increase serotonin levels have been shown to elevate reward thresholds in rats (Harrison and 
Markou, 2001). Thus, increased serotonergic transmission exerts an inhibitory influence on 
reward processes leading to anhedonia. Together, these findings are contradictory to clinical 
observations that drugs that enhance serotonin neurotransmission, serotonin reuptake 
inhibitors, are considered the first line of treatment for depressed HIV+ subjects (Arseniou et 
al., 2014). However, the response to antidepressant treatment in depression is complicated 
and aspects of plasticity-mediated brain changes may be more relevant than discrete actions 
on serotonergic function (Manji et al., 2001). Furthermore, altered serotonin synthesis has 
been identified as a potential mediator of neuroinflammation mediated depression (Dantzer et 
al., 2008). Intracerebroventricular TAT administration in mice is associated with increased 
inflammatory mediators (Lawson et al., 2011), and some inflammatory mediators can 
increase serotonergic function (Dunn et al., 2005). Thus, inflammation-associated increases 
in serotonergic transmission may mediate TAT-induced anhedonia in the present study. 
A host of molecular pathways have been identified through which the effects of TAT and 
methamphetamine either overlap or synergize (Mediouni et al., 2015). However, little is 
known about the combined effects of TAT and methamphetamine on behavioral outcomes. 
Our findings suggest that previous TAT exposure increases the sensitivity to 
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methamphetamine-induced reward enhancement. Importantly, this effect was observed nearly 
four weeks after the final doxycycline treatment, assuring that the TAT protein was not 
present during the acute challenges (Paris et al., 2014c). It is important to consider that TAT-
induced differences after acute methamphetamine challenge were only observed for reward 
thresholds and not timeout responses or the latency to respond. Thus, it is unlikely that 
alterations in impulsivity-like disinhibition of responding (Amitai et al., 2009) or indirect 
effects on motor function contributed to the present results. Similar reward alterations have 
also been observed by others during acute TAT expression. For example, acute TAT 
expression increased the conditioned rewarding effects of both ethanol and cocaine in the 
conditioned place preference test (Paris et al., 2014a, McLaughlin et al., 2015). Furthermore, 
TAT infusions into the Acb increased locomotor activation induced by acute cocaine (Harrod 
et al., 2008). We have previously found enhancement of the rewarding properties of 
methamphetamine independent of changes in the reward or motivation for a natural food 
reinforcer in gp120 expressing mice (Kesby et al., 2014). Infusions of TAT or gp120 impair 
dopamine function in the rat striatum (Bansal et al., 2000) which may be mediated by similar 
mechanisms (Wallace et al., 2006). Taken together, these data indicate that HIV-associated 
proteins, such as TAT or gp120, may enhance the rewarding properties of methamphetamine, 
and other drugs of abuse, by impairing dopaminergic function in mesolimbic circuitry. Our 
findings suggest that the use of TAT vaccines, currently being tested in clinical trials (Loret 
et al., 2016), if administered early enough may prevent alterations in brain reward function, 
and decrease the rewarding properties of methamphetamine or other drugs of abuse in the 
HIV+ population. 
Prior TAT exposure did not alter the response to the effects of nicotine on reward function 
suggesting that TAT-induced increases in reward sensitivities to drugs of abuse are not 
ubiquitous. Unlike others (Fowler et al., 2013), we did not observe nicotine-induced reward 
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enhancement in control TAT- mice. However, our findings do not preclude that other 
methods may reveal TAT-induced alterations in sensitivity to the rewarding effects of 
nicotine or the potential for alterations in the response to nicotine during acute TAT protein 
expression. Recent work demonstrated decreased nicotine-induced locomotor sensitization in 
HIV-1 transgenic rats (Midde et al., 2011) and after infusions of TAT into the ventral 
tegmental area in rats (Zhu et al., 2015). These findings suggest that the TAT protein may 
reduce sensitivity to nicotine. It has been demonstrated that nicotine-based reward 
enhancement is not dependent on direct effects on the dopamine transporter, unlike 
methamphetamine (Gerasimov et al., 2000). TAT protein has been shown to directly alter 
dopamine transporter function (Zhu et al., 2009, Midde et al., 2012) which may explain the 
methamphetamine-specific effects on reward enhancement observed in the present study. Thus, 
TAT protein appears to interact differently with nicotine compared to methamphetamine, 
perhaps due to their differing mechanisms in activating the dopamine system. 
TAT expression did not impair delay-dependent working memory in the present study, 
although working memory deficits are common in HIV-infected individuals (Heaton et al., 
1995, Heaton et al., 2011). Anhedonia and motivational deficits, observed in the ICSS 
procedure during acute TAT expression, can impair behavioral performance in reward-based 
cognitive tasks. However, in the DNMTP task, behavioral measures reflective of motivational 
state, including the total trials completed, rewards gained, latencies to respond and to collect 
the reward, were not significantly different between TAT- and TAT+ mice. In contrast to our 
findings, spatial memory impairments have been observed after TAT exposure in mice 
(Carey et al., 2012) but this may be due to learning impairments induced by concomitant 
TAT protein expression rather than specific memory impairments (Kesby et al., 2016). Thus, 
the TAT protein may not contribute to delay-dependent spatial working memory in HIV-
infected individuals although it may contribute to other forms of memory encoding and 
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retrieval. Alternatively, a longer period of TAT protein exposure (via doxycycline containing 
food or water) may lead to more robust neuropathology and thus impact working memory. If 
this is the case, TAT vaccines (Loret et al., 2016) may prevent aspects of cognitive decline in 
HIV+ individuals. Our results suggest that short-term TAT protein exposure is insufficient to 
induce delay-dependent working memory impairments but sufficient to induce persisting 
alterations to the rewarding properties of methamphetamine. 
5. Conclusions 
Our findings in mice suggest that TAT protein expression is sufficient to induce anhedonia 
and lead to a long-lasting increase in sensitivity to the rewarding effects of 
methamphetamine. However, TAT-mediated effects on reward function do not predict 
impairments in delay-dependent working memory and, therefore, do not represent an 
impairment in general brain function. Our findings suggest that TAT expression may 
contribute to comorbid depression in treated HIV-infected subjects, even those with adequate 
viral suppression. Furthermore, impairments in reward function may increase the risk of 
developing methamphetamine dependence in HIV-infected subjects. The DOX-inducible, 
TAT-expressing mouse represents a valuable tool to investigate neurobiological mechanisms 
underlying comorbid depression and methamphetamine dependence after HIV infection. 
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FIGURE LEGENDS 
Figure 1. Effects of TAT protein expression on reward thresholds, latency to respond 
and timeout responses.  
TAT protein expression significantly elevated reward thresholds in TAT+ mice (A). This 
effect was most evident during doxycycline administration. The latency to respond was 
increased during doxycycline administration but no differences between TAT- and TAT+ 
mice were observed (B). Timeout responses decreased during doxycycline administration (C) 
and remained lower than baseline testing for the two weeks following the doxycycline 
regimen.  
* p < 0.05, *** p < 0.001 significant difference between TAT- and TAT+ mice. 
#
 p < 0.05, ## p < 0.01, ### p < 0.001 significant difference when compared to baseline.  
 
Figure 2. Effects of TAT protein expression after acute nicotine and methamphetamine 
on reward thresholds, latency to respond and timeout responses.  
Acute nicotine failed to significantly alter reward thresholds (A) but dose-dependently 
increased response latencies (C) and decreased timeout responses (E). TAT protein 
expression potentiated methamphetamine-induced reward enhancement (B) as indicated by 
significantly lower reward thresholds in TAT+ mice compared with TAT- mice after 
methamphetamine. TAT+ mice showed a greater response latency than TAT- mice after 0.5 
mg/kg methamphetamine (D). Methamphetamine also significantly decreased timeout 
responses in all mice (F).  
* p < 0.05, *** p < 0.001. 
#
 p < 0.05 significant main effect of TAT. 
a
 p < 0.05 compared to saline response in TAT- mice. 
b
 p < 0.05 compared to saline response in TAT+ mice. 
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Figure 3. Acute and persistent effects of TAT protein expression on dopaminergic and 
serotonergic function.  
Acute TAT expression (3 days after doxycycline treatment) increased dopamine (DA) and 3-
methoxytyramine (3-MT) levels in the caudate putamen of TAT+ mice compared with TAT- 
mice (A). In the nucleus accumbens (B), acute TAT expression increased levels of serotonin 
(5-HT) and 5-hydroxy-indoleacetic acid (5-HIAA) in TAT+ mice compared with TAT- mice. 
There was also a trend toward decreased dopamine levels in the nucleus accumbens of TAT+ 
mice compared with TAT- mice. There were no persistent effects of prior TAT expression 
(40 days after doxycycline treatment) in the caudate putamen (C) or nucleus accumbens (D) 
of TAT+ mice compared with TAT- mice. DOPAC, dihydroxyphenylacetic acid; HVA, 
homovanillic acid. 
* p < 0.05, ** p < 0.01, # p < 0. 1. 
 
Figure 4. Effects of TAT protein expression on trials completed during delayed 
nonmatch-to-position testing. 
Doxycycline administration significantly decreased the trials completed in all mice. This was 
most evident during the doxycycline regimen but also persisted during the following week of 
testing. No differences between TAT- and TAT+ mice were observed at any stage of testing.  
** p < 0.01, *** p < 0.001 when compared to baseline. 
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Figure 5. Effects of TAT protein expression on delay-dependent memory prior to TAT 
expression. 
Delay-dependent memory during the baseline period (A), during doxycycline administration 
(B), after doxycycline administration (C) and during subsequent testing with increased delays 
(D; DNMTP2). There were no differences between TAT- and TAT+ mice at any stage of 
testing. Within each panel all delays are significantly different from one another (p < 0.05) 
except for comparisons highlighted as not significant (ns). 
 
Figure 6. Effects of TAT protein expression on latencies during delayed nonmatch-to-
position testing. 
The latency to press the sample lever (A, left), press the correct choice lever (B, middle left), 
press the incorrect choice lever (C, middle right) and to collect the reward (D, right) in TAT- 
and TAT+ mice. No significant differences between TAT- and TAT+ mice were observed in 
any measure or at any stage of testing. Doxycycline (DOX) administration increased the 
latencies for all measures when compared to baseline testing (base) but these differences did 
not persist post-DOX (pDOX). Increasing the delays during DNMTP2 (2) increased the 
latency to press the sample lever and decreased the latency to press the incorrect choice lever 
when compared to baseline testing.  
##
 p < 0.01, ### p < 0.001 when compared to all other blocks. 
* p < 0.05 compared to baseline testing. 
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Highlights 
• TAT protein expression in the brain produced an anhedonia-like phenotype. 
• TAT protein expression altered mesolimbic dopamine and serotonin levels. 
• Prior TAT expression increases the rewarding effects of methamphetamine. 
• Prior TAT expression does not impair delay-dependent working memory. 
• TAT expression may contribute to comorbid depression in HIV+ subjects. 
• TAT expression may exacerbate methamphetamine dependence in HIV+ subjects. 
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